Influencing factors and countermeasures of postherpetic neuralgia
Weng Xun1, Zhang Li2
1.Dermatological Department, Taishun County People's Hospital of Zhejiang, 325500, China;
2.Dermatology & STD Department, Second Affiliated Hospital of Wenzhou Medical University
Abstract：Objective To discuss the influencing factors and countermeasures of postherpetic neuralgia.Methods Totally 546 patients with herpes zoster were selected in our Hospital from December 2015 to December 2017. The clinical data of patients were collected, the influencing factors of postherpetic neuralgia occurrence in herpes zoster was investigated, and its countermeasures was analyzed.Results Of the 546 herpes zoster patients, 120 patients had postherpetic neuralgia and the incidence was 21.98%. Univariate analysis showed that, age, sex, diabetes mellitus, herpes zoster typing, lesion area, prodromal pain, acute pain degree and initial treatment time were associated with postherpetic neuralgia in herpes zoster (P<0.05). Logistic multivariate analysis showed that, aged over 50 years old, diabetes mellitus, lesion area over 5%, prodromal pain and initial treatment time less than 3 days were the independent risk factors for postherpetic neuralgia in herpes zoster (P<0.05).Conclusion The risk of postherpetic neuralgia in herpes zoster is high, and it is related to many factors. In particular, the intervention should be strengthened in patients over 50 years old, with diabetes mellitus, skin lesion area over 5%, prodromal pain, and initial treatment time less than 3 days, etc.
［2］WADIH A, REHM PK, DENG C, et al. Active herpes zoster infection with cutaneous manifestation and adenopathy on FDG PET/CT［J］. Radiol Case Rep,2015 ,10(3) :27-29.
［7］TAKAO Y, MIYAZAKI Y, OKEDA M, et al. Incidences of Herpes Zoster and Postherpetic Neuralgia in Japanese Adults Aged 50 Years and Older From a Communitybased Prospective Cohort Study:The SHEZ Study［J］.J Epidemiol,2015,25(10) :617-25.
［8］RICE A SC,DWORKIN RH,MC CARTHY TD,et al.EMA401,an orally administered highly selective angiotensin II type2 receptor antagonist,as a novel treatment for postherpetic neuralgia:a randomised,doubleblind,placebocontrolled phase 2 clinical trial［J］.The Lancet,2014,383(9929):1637-1647.
